Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.59 |
| ▸ | CSF1R | P07333 | 7/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282376 | 0.82 | CDK8 (0.61) | KDRPDGFRAFLT3BRAFRAF1 | |
| SCHEMBL15494360 | 0.81 | KDR (0.42) | KDRCSF1RPDGFRAFLT3KDM4E | |
| SCHEMBL281869 | 0.80 | BRAF (0.63) | KDRPDGFRAFLT3BRAFRAF1 | |
| SCHEMBL282287 | 0.80 | RAF1 (0.56) | KDRPDGFRAFLT3TNNI3KBRAF | |
| SCHEMBL10084367 | 0.78 | KDR (0.50) | KDRCSF1RPDGFRAFLT3KDM4E | |
| SCHEMBL11106394 | 0.73 | RAB9A (0.85) | KDM4E | |
| SCHEMBL282261 | 0.73 | TDP1 (0.42) | KDM4E | |
| SCHEMBL4929333 | 0.73 | KDR (0.71) | KDRCSF1RFLT3TNNI3KBRAF | |
| SCHEMBL21295574 | 0.72 | NPC1 (0.76) | KDM4ERAF1 | |
| SCHEMBL21295380 | 0.72 | CA12 (0.71) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | KDR 3633/4885CSF1R 2180/4885PDGFRA 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.